Shares of AtheroGenics shot up this morning on the news that an interim analysis of late-stage data for AGI-1067 showed a statistically significant reduction in Hemoglobin A1c--a standard measure for blood sugar control. Their ANDES study examines the effect of two daily doses of the therapy over a period of six months. The interim analysis covers 806 patients who had completed three months of therapy. Mean changes for patients in the 150 mg, 75 mg, and placebo arms were 0.5 percent, 0.3 percent, and 0.1 percent.
"We are encouraged by these early results, which show a meaningful reduction in blood sugar for patients with diabetes taking AGI-1067," said Alexander Fleming, M.D., Acting Chief Medical Officer. "The interim data also suggest that this three month assessment may not be capturing the full effect of AGI-1067 on A1c reduction."
"These interim results reinforce our belief that AGI-1067 may have the potential to introduce a new therapeutic approach for the treatment of patients with diabetes," said CEO Russell M. Medford, M.D., Ph.D.
- read the press release